深圳信立泰药业股份有限公司 关于控股股东部分股份解除质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 证券代码：002294 证券简称：信立泰 编号：2024-055 深圳信立泰药业股份有限公司（下称"公司"）于近日接到公司控股股东信 立泰药业有限公司（下称"香港信立泰"）的通知，获悉其将所持有的本公司部 分股份解除质押。具体情况如下： 一、本次股东股份解除质押基本情况 | | | 是否为控股 | 本次解除质 | 占其所 | 占公司 | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东名 称 | | 股东或第一 大股东及其 | 押股份数量 | 持股份 | 总股本 | 起始日 | 解除日期 | 质权人 | | | | 一致行动人 | （万股） | 比例 | 比例 | | | | | 信立泰 药业有 | | 控股股东、 第一大股东 | 750.00 | 1.18% | 0.67% | 2022-11-23 | 2024-12-19 | 杭州银行股份 有限公司上海 | | ...

Group 1: Product Development and Market Strategy - The company is focusing on chronic disease areas, particularly cardiovascular, nephrology, and diabetes, with plans to launch 1-2 new products annually, responding to the growing demand due to an aging population [1] - The company aims to maintain competitiveness by providing high-quality drugs that meet clinical needs and by ensuring continuous innovation and risk management [2] - The sales volume of the drug Fuzhuo has exceeded 5000 units, and the management is confident about its sales performance in the coming year [2] Group 2: Financial Performance and R&D Investment - In the first half of 2024, the R&D investment as a percentage of revenue decreased, primarily due to revenue growth, but actual R&D spending has increased after excluding last year's milestone payments [3] - The company plans to continue increasing investment in innovative product development despite the decrease in R&D investment ratio [3] - The number of shareholders as of December 10 is 25,892 [3] Group 3: Cost Management and Operational Efficiency - The company is implementing measures to optimize cost structures in response to rising management and sales expenses, including improving sales efficiency and controlling costs through lean production [4] - The company is focused on maintaining stable gross margins despite fluctuations in raw material costs by optimizing operations and enhancing quality [4] Group 4: Market Expansion and Digital Transformation - The company is exploring digital transformation to enhance internal management efficiency and customer experience [5] - Plans for international clinical new drug applications are in progress, with ongoing evaluations based on project data [5] Group 5: Sales and Marketing Strategies - The company is optimistic about the sales growth of its new products, which are expected to contribute increasingly to revenue and profit [4] - The company anticipates that the two new products will likely participate in medical insurance negotiations next year, which could boost sales [5]

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 证券代码：002294 证券简称：信立泰 编号：2024-054 深圳信立泰药业股份有限公司 关于第二期员工持股计划 存续期即将届满的提示性公告 鉴于深圳信立泰药业股份有限公司（下称"公司"）第二期员工持股计划（下 称"本期员工持股计划"）存续期将于 2025 年 6 月 14 日届满，根据中国证监会 《关于上市公司实施员工持股计划试点的指导意见》、深圳证券交易所《深圳证 券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等有关要 求，现就有关情况公告如下： 一、 第二期员工持股计划概述 1、公司分别于 2020 年 12 月 27 日、2021 年 1 月 21 日召开第五届董事会第 九次会议、2021 年第一次临时股东大会，审议通过了《关于〈深圳信立泰药业股 份有限公司第二期员工持股计划（草案）及摘要〉的议案》等相关议案。 2、第二期员工持股计划的股份来源为公司前期已回购的公司股份，即公司 于 2019 年 11 月 12 日至 2020 年 10 月 5 日期间回购的股份 17,503,178 ...

证券代码：002294 证券简称：信立泰 编号：2024-053 深圳信立泰药业股份有限公司 关于参加 2024 年度 深圳辖区上市公司集体接待日活动的公告 为进一步加强与投资者的互动交流，深圳信立泰药业股份有限公司（下称"公 司"）将参加由深圳证监局和深圳证券交易所指导、深圳上市公司协会与深圳市 全景网络有限公司联合举办的"2024 年度深圳辖区上市公司集体接待日"活动， 现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （https://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP，参 与本次互动交流，活动时间为 2024 年 12 月 12 日（周四）14:30-17:00。 届时公司高管将在线就公司业绩、公司治理、发展战略、经营状况和可持续 发展等投资者关心的问题，与投资者进行沟通与交流，欢迎广大投资者踊跃参与。 特此公告 深圳信立泰药业股份有限公司 二〇二四年十二月四日 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 董事会 ...

Company and Industry Summary Company Overview - The company is involved in the pharmaceutical industry, focusing on chronic disease medications, particularly for hypertension and diabetes management. Key Points and Arguments Product Development and Market Entry - Two key products have been successfully included in the medical insurance directory, expected to generate approximately 100 million in revenue each within a year [1] - The company anticipates that the sales of these products will exceed initial expectations, with projections of reaching up to 500 million in revenue in the future [1] - The company has a robust pipeline with multiple products expected to launch, including hypertension medications and diabetes treatments, which will enhance the product line significantly [3][4] Clinical Trials and Data Expectations - The company is optimistic about upcoming clinical trial data, with a high probability of positive results expected by the end of December [2] - Safety and efficacy data from ongoing trials show promising results, with no significant differences observed between the treatment and placebo groups [12] - The company is preparing for potential FDA discussions regarding trial data and product approvals [19] Financial Projections - The company expects to achieve revenue growth of 10% next year, with new product launches contributing significantly to this growth [4] - Anticipated revenue for the current year is around 600 million, with projections for next year ranging between 200 to 300 million [25] - The company aims for a long-term growth trajectory of over 20% starting in 2026, driven by new product introductions and market expansion [28] Market Dynamics and Competitive Landscape - The company has a strong position in the hypertension market, with a significant patient population and a well-established product line [6][7] - The competitive landscape is challenging, with many companies vying for market share in chronic disease medications, but the company believes its innovative products will maintain a competitive edge [8][9] - The company is not significantly affected by competitors' failures in similar therapeutic areas, as its products are distinct and have established efficacy [10][22] Innovation and Future Outlook - The company is focusing on innovative drug development, including small molecules and gene editing technologies, to enhance its product offerings [5] - There is a strong emphasis on research and development, with plans to introduce several new products in the coming years [5][17] - The company is also exploring international markets for potential product licensing and partnerships, indicating a strategic approach to global expansion [17] Regulatory and Pricing Strategies - The company is actively engaging with regulatory bodies to ensure compliance and facilitate product approvals [15][19] - Pricing strategies are being carefully considered, with a focus on maintaining competitive pricing while ensuring profitability [13][14] Additional Important Insights - The company is aware of the complexities in the chronic disease medication market, including patient adherence and physician preferences, which will influence product uptake [24] - There is a recognition of the need for ongoing education and marketing efforts to promote new products effectively [22][24] - The company is committed to maintaining a strong cash flow to support ongoing research and development initiatives [8][27]

证券代码：002294 证券简称：信立泰 编号：2024-052 深圳信立泰药业股份有限公司 关于阿利沙坦酯氨氯地平片（复立坦®）、 苯甲酸福格列汀片（信立汀） 新纳入国家医保目录的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 根据国家医保局、人力资源社会保障部发布的《关于印发<国家基本医疗保 险、工伤保险和生育保险药品目录（2024 年）>的通知》（医保发〔2024〕33 号） （下称"《通知》"），深圳信立泰药业股份有限公司（下称"公司"）的创新 药复立坦®（通用名：阿利沙坦酯氨氯地平片）、信立汀（通用名：苯甲酸福格 列汀片），通过谈判新纳入《国家基本医疗保险、工伤保险和生育保险药品目录 （2024 年）》（下称"医保目录"）乙类范围。 具体情况如下： 一、产品情况 （一） 复立坦® 1、 基本情况 药品名称：阿利沙坦酯氨氯地平片 规格：每片含阿利沙坦酯 240mg 与苯磺酸氨氯地平（按氨氯地平计）5mg 医保类别：医保乙类 备注：限原发性高血压。 协议有效期：2025 年 1 月 1 日至 2026 年 12 月 31 日。 （二） 信立汀 1、 ...

普瑞基准科技（北京）有限公司增资的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 一、交易概述 （一） 基本情况 根据公司战略发展规划，深圳信立泰药业股份有限公司（下称"公司"或"信 立泰"）拟以自筹资金人民币 3,000 万元增资参股公司普瑞基准科技（北京）有 限公司（下称"普瑞基准"或"标的公司"），获得普瑞基准 3.2154%股权。本 次增资完成后，公司将直接持有普瑞基准 8.5745%股权。 增资前，公司及下属控股企业宁波梅山保税港区沃生静嘉股权投资合伙企业 （有限合伙）（下称"沃生静嘉"）、下属参股企业"平潭综合实验区沃生慧嘉 股权投资合伙企业（有限合伙）"（下称"沃生慧嘉"）分别持有普瑞基准 5.5556%、 3.8332%、2.3666%股权。 （二） 董事会审议情况 证券代码：002294 证券简称：信立泰 编号：2024-051 深圳信立泰药业股份有限公司 关于向参股公司 《关于向参股公司普瑞基准科技（北京）有限公司增资的议案》已经公司第 六届董事会第六次会议以 9 人同意，0 人反对，0 人弃权审议通过。 （三） 所必需的审批程序 本 ...

深圳信立泰药业股份有限公司 第六届董事会第六次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 证券代码：002294 证券简称：信立泰 编号：2024-050 根据公司战略发展规划，同意公司以自筹资金人民币 3,000 万元增资参股公 司普瑞基准科技（北京）有限公司（下称"普瑞基准"），获得普瑞基准 3.2154% 股权。本次增资完成后，公司将直接持有普瑞基准 8.5745%股权。 董事会授权公司管理层负责签署本次交易有关协议及具体履行协议的相关 事宜，授权期限至相关事宜全部办理完毕止。 （《关于向参股公司普瑞基准科技（北京）有限公司增资的公告》详见信息 披露媒体：《中国证券报》、《证券时报》和巨潮资讯网 www.cninfo.com.cn。） 备查文件 1、 经与会董事签字并加盖董事会印章的董事会决议； 特此公告 深圳信立泰药业股份有限公司 董事会 深圳信立泰药业股份有限公司（下称"公司"）第六届董事会第六次会议于 2024 年 11 月 21 日上午 9 时 30 分，以通讯及书面方式召开，会议通知于 2024 年 11 月 18 日以电子邮 ...

证券代码：002294 证券简称：信立泰 编号：2024-049 深圳信立泰药业股份有限公司 关于使用部分闲置募集资金现金管理的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 深圳信立泰药业股份有限公司（下称"公司"或"信立泰"）于 2024 年 3 月 24 日召开第六届董事会第二次会议，审议通过《关于使用部分闲置募集资金现 金管理的议案》，同意公司使用不超过人民币 10 亿元（含本数）的闲置募集资 金进行现金管理（在上述额度内，资金可循环滚动使用），相关额度的使用期限 不超过 12 个月，期限内任一时点的交易金额不应超过现金管理额度；并授权经 营管理层负责具体实施相关事宜，授权期限为本次董事会审议通过之日起一年内 有效。 | 委托方 | 受托方 | 关联 | 产品 | 购买金额 | 起息日 | 产品期限 | 实际最晚 | 进展 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 关系 | 类型 | （万元） | | | 转让日期 | 情况 | | | | | | | | ...

Investment Rating - The report maintains a "Recommend" rating for the company with a target price of 41.3 RMB, compared to the current price of 32.4 RMB [1] Core Views - The company's Q1-3 2024 revenue reached 3.001 billion RMB, a 22.18% YoY increase, with net profit attributable to shareholders at 510 million RMB, up 6.37% YoY [1] - Q3 2024 revenue was 958 million RMB, a 24.15% YoY increase, with net profit attributable to shareholders at 166 million RMB, up 17.01% YoY [1] - The company's performance driver has shifted to innovative drugs, with Xinlitan maintaining strong growth and Enadustat entering the early stage of medical insurance-driven volume growth [1] - The company's R&D pipeline is progressing steadily, with SAL0107 and Foglitin expected to accelerate volume growth if successfully included in the medical insurance list [1] Financial Performance - The company's 2024-2026 net profit attributable to shareholders is forecasted to be 638 million RMB, 708 million RMB, and 879 million RMB, representing YoY growth of 10.0%, 10.9%, and 24.2% respectively [1] - The company's 2025 reasonable valuation is estimated at 46 billion RMB, with innovative drugs accounting for 39.6 billion RMB of the valuation [1] - The company's 2024E revenue is projected to be 4.019 billion RMB, a 19.4% YoY increase, with net profit attributable to shareholders at 638 million RMB, up 10.0% YoY [2] R&D Pipeline - SAL0108 and S086 for hypertension are expected to be approved in H2 2024-H1 2025 and participate in the 2025 medical insurance negotiation [1] - S086 for heart failure is currently in Phase III clinical enrollment, while SAL003 has completed Phase III patient enrollment and is expected to apply for production approval in H2 2025 [1] - JK07 is expected to read out Phase II data by the end of 2024, with SAL0114, SAL0112, and JK08 progressing in clinical trials [1] Valuation Metrics - The company's 2025E P/E ratio is 52x, with a P/B ratio of 5x and EV/EBITDA of 36x [2] - The company's 2025E ROE is projected to be 8.6%, with ROIC at 13.9% [5]